Source comparison
Melanotan-2 FDA Approved Status Comparison — Regulatory Pathways
Semaglutide (Wegovy) Approved 2021 Phase III completed Prescription via licensed physician Melanotan-2 never completed Phase III; no approval pathway exists Tirzepatide (Mounjaro) Approved 2022 Melanotan-2 stalled in Phase II due to side effect profile BPC-157
This comparison does not assign a generated winner or score.
- Semaglutide (Wegovy)
- Approved 2021
- Phase III completed
- Prescription via licensed physician
- Melanotan-2 never completed Phase III; no approval pathway exists
- Tirzepatide (Mounjaro)
- Approved 2022
- Melanotan-2 stalled in Phase II due to side effect profile
- BPC-157
- Not approved
- Phase I only
- Research use only
- Melanotan-2 has more clinical data but same unapproved status
- Melanotan-1 (Scenesse)
- Approved (EU only)
- Prescription for erythropoietic protoporphyria
- Melanotan-2 is the unmodified analog; never pursued EU approval
- NAD+
- Phase II ongoing
- Research use or compounded off-label
- Melanotan-2 has no active clinical development; NAD+ trials continue
- Professional Assessment
- Melanotan-2 has stronger preclinical and Phase I/II data than most grey-market peptides but failed to advance due to unacceptable side effect frequency for cosmetic use. The peptide is pharmacologically active and well-characterized but will not achieve FDA approval without renewed commercial sponsorship and completed Phase III trials. Unlikely given the competitive landscape for melanocortin agonists.